EichorEICHOR
Location: Oviedo Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Oviedo

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Observational Study Protocol: LIVER-R
Phase N/A · Research Site · AstraZeneca · NCT06252753
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
Phase N/A · Hospital Universitario Central de Asturias · Spanish Oncology Genito-Urinary Group · NCT06724159
Spanish Series of Patients Treated With the Radionuclide Lutetium177
Phase N/A · Hospital Universitario Central de Asturias · Sociedad Española de Medicina Nuclear e Imagen Molecular · NCT04949282
Non-Invasive Ventilation Versus High-flow Nasal Oxygen in Intensive Care Units
NA · Hospital Universitario Central de Asturias · Poitiers University Hospital · NCT05686850
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Hospital Universitario Central de Asturias · Amgen · NCT07037433
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice
Phase N/A · Hospital Universitario Central de Asturias · Outcomes'10 · NCT07252765
Spanish Registry of Esophagogastric Cancer
Phase N/A · Hospital Universitario Central de Asturias · Fundación Sociedad Española de Oncologia Médica · NCT04958720
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary
Phase N/A · Hospital Universitario Central de Asturias · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT06686615
Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
Phase N/A · Hospital Universitario Central de Asturias · Biobizkaia Health Research Institute · NCT07240038
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · Research Site · AstraZeneca · NCT06868277
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in
Phase N/A · Hospital Univ. Central de Asturias · Hoffmann-La Roche · NCT07284121
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · Hospital Universitario Central de Asturias · Regeneron Pharmaceuticals · NCT06091865
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
Phase 3 · Central University Hospital of Asturias · Octapharma · NCT04918173
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcera
Phase 3 · Hospital Universitario Central de Asturias · Eli Lilly and Company · NCT06937086
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
NA · Hospital Universitario Central de Asturias · Grupo Español de Investigación en Diagnóstico y Tratamiento · NCT07465848
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor
Phase 2 · Hospital Universitario Central de Asturias-Medical Oncology · Merck Sharp & Dohme LLC · NCT04924075
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes
Phase N/A · Hospital Universitario Central de Asturias · Bristol-Myers Squibb · NCT05489705
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (
Phase 3 · Investigational Site Number : 7240005 · Sanofi · NCT06290128
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · Hosp. Univ. Central de Asturias · Janssen Research & Development, LLC · NCT06319820
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesop
Phase 3 · Hospital Universitario Central de Asturias · Daiichi Sankyo · NCT06731478
Usefulness of PET-CT for Invasive Fungal Infection
Phase N/A · Hospital Universitario Central de Asturias · Puerta de Hierro University Hospital · NCT05688592
A Mobile App to Reduce and/or Quit Cannabis Use
NA · Faculty of Psychology, University of Oviedo · Alba González-Roz, PhD · NCT06733792
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase 2/Phase 3 · Hospital Universitario Central de Asturias · Exelixis · NCT06943755
CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL
Phase 2 · Hospital Universitario Central de Asturias · GELLC (Grupo Español de Leucemia Linfocítica Crónica) · NCT06926205
Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
Phase 4 · Hospital Universitario Central de Asturias · Hospital Universitario de Fuenlabrada · NCT05250648
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adu
Phase 2/Phase 3 · Hospital Universitario Central de Asturias (HUCA) · Moleculin Biotech, Inc. · NCT06788756
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Phase 2 · Hospital Universitario Central de Asturias · Karyopharm Therapeutics Inc · NCT05980806
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treat
Phase 2 · Central University Hospital of Asturias · BioMarin Pharmaceutical · NCT06668805
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Parti
Phase 1/Phase 2 · Hospital Universitario Central de Asturias · Regeneron Pharmaceuticals · NCT05828511
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
NA · H. Central de Asturias · PETHEMA Foundation · NCT04179929
Look up another city
Look up another condition